Ryzumvi Solution/ Drops
Product Images NDC 83368-075

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Ryzumvi (NDC 83368-075). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Oyster Point Pharma, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Ryzumvi Ophthalmic Solution 0.75% Carton Label (Image 01)

The text provides information about a pharmaceutical product called Ryzumvi, which is a phentolamine ophthalmic solution. It contains 10mg of phentolamine mesylate per mL. The product is meant for topical use in the eyes and is stored refrigerated. Each box contains 6 pouches with 5 single-patient-use vials in each pouch. The product should be used within 14 days after opening the pouch and should not be frozen. It is important to discard the vial immediately after use as it does not contain any antimicrobial preservatives.*

FDA Label Image

Phentolamine Mesylate Structural Formula (Image 02)

FDA Label Image

Figure 1. Percentage Of Subjects With Study Eyes Returning To ≤0.2 Mm From Baseline Pupil Diameter By Time Point In The Mira-2 And Mira-3 Trials (Image 03)

FDA Label Image

Figure 2: Pupil Dilation By Time Point With Phenylephrine As Mydriatic Agent In Mira-2 And Mira-3 Trials (mitt Population) (Image 04)

FDA Label Image

Figure 3: Pupil Dilation By Time Point With Tropicamide Or Paremyd As Mydriatic Agent In Mira-2 And Mira-3 Trials (mitt Population) (Image 05)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.